Updated : 2015-05-01 20:19
Fake medicine hits retail investors hard
By Choi Kyong-ae
Individual investors took a severe beating from the fake herbal medicine produced by Naturalendo Tech, with their combined investment losses estimated at more than 600 billion won ($559 million).
“About 9,400 retail investors held a combined 54 percent stake in Naturalendo Tech as of the end of last year. They likely suffered hefty losses as the company’s stock prices fell sharply Thursday after the authorities said the herbal medicine contained uncertified ingredients,” an official at the tech-heavy KOSDAQ market said. Shares in Naturalendo Tech, a KOSDAQ-listed healthcare product company, plunged by the daily limit of 15 percent to 34,100 won, Thursday. The market was closed Friday for Labor Day.
The plunge came immediately after the Ministry of Food and Drug Safety said the same day that it had found the unauthorized ingredient cynanchum auriculatum in EstroG-100, a herbal medicine taken for menopause, in the company’s storehouse.
The medicine should contain cynanchum wilfordii and dong quai, not cynanchum auriculatum though it is edible.
The ministry’s finding comes after the Korea Consumer Agency (KCA) stated a week earlier that EstroG-100 didn’t contain extracts of cynanchum wilfordii, a medical herb proven to be helpful in reliving menopausal symptoms.
On Thursday, Naturalendo Tech said it will respect the ministry’s conclusion. The KCA said it will take all possible measures, including legal action against the company, to help affected customers.
“We were so confident about the ingredients offered by our contracted farmers that we didn’t have a ‘plan B’ in case there was controversy over the ingredients. We may come up with measures to handle this issue as early as next week,” Naturalendo Tech spokesman Kim Song-soo told The Korea Times, Friday.
Some contracted farmers provided cynanchum auriculatum instead of cynanchum wilfordii.
As a result, quality control of ingredients is expected to be the most important thing for the herb supplements maker.
In 2014, a total 94 billion won worth of EstroG-100 products were sold through home shopping channels. Unlike department stores and large discount stores which began to return the price customers paid for the products, home shopping companies are taking a wait-and-see attitude as they expect an impact on their bottom line if massive refunds are made, according to reports.
“Given the products are also sold in major markets such as the U.S. and Canada, the fact that the ministry found wrong ingredients in the company’s storehouse could have a grave impact on overseas sales,” the KOSDAQ official said.
Meanwhile, the Financial Services Commission is looking into a massive stock selling by Naturalendo executives ahead of the KCA disclosure and the ministry’s announcement, according to the Financial Supervisory Service.
Natural Endotech affair exposes cracks in Kosdaq
Secondary market’s reliance on leveraged retail investors risky
BY LEE HO-JEONG, KIM CHANG-GYU AND YEOM JI-HYUN [email@example.com]
The bullish rally on Seoul’s tech-heavy junior market that started in mid-March when the Korean central bank lowered the policy rate seemed like it was just the beginning and could continue throughout the rest of the year.
Today, the upswing seems like a distant mirage as the Kosdaq has been on a downward spiral that started last week.
The Kosdaq has been on a slippery slope since Wednesday. Only once – on Monday – did it recover in the six trading days leading up to Thursday. The market was closed Friday for Labor Day. The last trading day of this week on Thursday saw the index stumble 0.96 percent, or 6.68 points, to close at 689.01.
It took only one controversy surrounding a biotech company to pull the Kosdaq down. It has long been one of the biggest concerns that the secondary market is vulnerable and easily manipulated as the recent situation has once again demonstrated.
The Kosdaq had enjoyed a bullish rally since the Bank of Korea on March 12 shaved 0.25 percentage point off the policy rate from its already all-time low of 2 percent to a another new low of 1.75 percent.
Retail investors rushed to stocks, helping the market close 1.38 percent higher at 628.15.
Since then, the Kosdaq had been advancing. In just a month it exceeded the 700 mark for the first time in seven years. On April 17, the market gained 1.23 percent to close at 706.9. It was a significant recovery for the junior market, which had struggled since 2008. In fact, the Kosdaq saw a steeper rise than the Seoul benchmark Kospi. Compared to the beginning of the year, the Kosdaq marked 29 percent growth when it reached the year’s high at the time on April 21. The Kospi grew 12.8 percent compared to the beginning of this year to its highest point on April 23, when the market closed at 2,173.41. The Kospi also responded slower than the Kosdaq to the policy rate cut. While Kosdaq stocks advanced the same day, the Kospi retreated. It was half a percent down to close at 1,970.59, although the following day it quickly rose 0.77 percent to close at 1,985.70.
Yet it was not until the beginning of April that the primary market started to gain momentum.
The growth in both the Kosdaq and Kospi is welcome, especially since it exceeds that of the MISCI AC World Index that has advanced 6.1 percent this year.
But the party didn’t last long. When the Korean consumer protection agency announced that biotech company Natural Endotech had used an unauthorized herbal ingredient that looked very similar to the one it promotes, the company’s stock price plunged to the daily limit and dragged the Kosdaq down with it.
Starting April 22, Natural Endotech’s stock – except for Tuesday – sank to the daily limit for six trading days. As of Thursday, the company’s value had plummeted 60 percent compared to April 21.
The Kosdaq during the same period also retreated. In the past seven trading days, the market closed higher only once, on Monday. Compared to April 21, the day before the controversy started, the Kosdaq index was down 3.57 percent.
Interestingly, based on capitalization, Natural Endotech isn’t a stock that should be expected to have a heavy influence on the Kosdaq.
On April 21, Natural Endotech’s shares accounted for less than 1 percent of the Kosdaq. Endotech’s market capitalization was 1.6 trillion won ($1.5 billion) at the time when the secondary market’s cumulative capitalization was 192 trillion won.
A week later, the biotech company’s capitalization share has shrunk further to nearly a third of what it used to be. It now accounts for 0.36 percent as its market capitalization has diminished to 659.2 billion won. At the same time, Kosdaq market capitalization shrank to 185.5 trillion won as of Thursday.
Despite what many considered to be Natural Endotech’s potential for no more than a negligible influence on the secondary market, it turned out to be a case of the tail wagging the dog.
How could this happen? Experts say the biggest vulnerability of the Kosdaq is largely caused by its heavy concentration of retail investors.
The problem with retail investors is many of them choose to buy stock using borrowed money. In hopes of riding the wave of optimism, many resort to taking out unsecured loans from financial institutions, including brokerage firms, to finance their stock purchases.
Experts say the biggest problem is that many of the Korean retail investors purchase stocks with borrowed money without having substantial information on a company. They tend to invest largely on rumors and speculation. As a result, those same reasons can quickly become their undoing. The recent controversy has exposed such problems within the secondary market, as retail investors have been offloading shares largely influenced by the emotions of the moment.
Unlike the primary market Kospi, where the majority of the investors are institutional and foreign, most investors purchasing stocks on the Kosdaq are retail investors. As of Thursday, retail investors accounted for 87.1 percent, followed by foreign investors at 7 percent and institutional investors at slightly less than 5 percent. This is in stark contrast to the Nasdaq, where more than 70 percent of investors are institutional.
So why the difference? Unlike the Kosdaq, the reason such heavy investors actively participate in the Nasdaq is because many of the world’s leading companies, including Apple, Google, Amazon and Facebook, are listed. The situation is different from the Korean market.
Celltrion is the No.1 company on the junior market by capitalization at 9.34 trillion won. But when it is compared to the main bourse Kospi, it would be between 27th-ranked LG Electronics with a market capitalization of 9.88 trillion won and Hana Financial Group at 9.19 trillion won.
Meanwhile, retail investors who buy stocks on unsecured credit have been growing rapidly, even larger than the Kospi.
As of Thursday, the stocks purchased using unsecured loans on the Kosdaq amounted to 3.95 trillion won, compared to 3.53 trillion won in the Kospi.
Considering that the Kosdaq market is crowded with retail investors, a bearish situation is likely to lead to a crisis.
“The stock market has been on a steep rise thanks to a rapid increase of participation by retail investors, who were relatively absent in the past couple of years,” said technical analyst Kim Young-il of Daishin Securities. “The return of retail investors is good news for the local market’s liquidity and it will act as a positive variable for the market.
“However, there needs to be an awareness of the potential problems that come with such excessive growth of retail investors in such a short time. There have been several cases in the past where liquidity problems surfaced later when loans related to the stock market, including purchasing stocks on unsecured loans, have grown significantly.”